Potential New Way to Suppress Tumor Growth Discovered
News Jun 10, 2013
Writing in this week's online Early Edition of the Proceedings of the National Academy of Sciences (PNAS), Willis X. Li, a professor in the Department of Medicine at UC San Diego, reports that a particular form of a signaling protein called STAT5A stabilizes the formation of heterochromatin (a form of chromosomal DNA), which in turn suppresses the ability of cancer cells to issue instructions to multiply and grow.
Specifically, Li and colleagues found that the unphosphorylated form of STAT promotes and stabilizes heterochromatin, which keeps DNA tightly packaged and inaccessible to transcription factors. "Therefore, genes ‘buried' in heterochromatin are not expressed," explained Li.
Phosphorylation is a fundamental cellular function in which a phosphate group is added to a protein or molecule, causing it to turn it on or off or to alter its function. An unphosphorylated STAT lacks this phosphate group.
Li said that in previous studies with fruit flies, the unphosphorylated form of STAT caused chromatin to condense into heterochromatin, while the phosphorylated version prompted dispersal and loss of heterochromatin, furthering gene expression.
"Unphosphorylated STAT promotes and stabilizes heterochromatin formation, which in turn suppresses gene transcription," said Li. "When we expressed either HP1 (the central component of heterochromatin) or unphosphorylated STAT5A in human cancer cells, many genes important for cancer growth are suppressed. These cancer cells do not grow as fast or big as their control parental cancer cells in mouse xenograft models."
Most of the known tumor suppressors, such as p53 or Rb, function by inhibiting cell cycle progression or by spurring cell death, or apoptosis. Li said their findings reveal a potential new way to inhibit cancer gene expression, and may represent a new class of tumor suppressors.
"We are in the process of identifying small molecule drugs that may promote heterochromatin formation without stopping cell division or causing cell death," he said. "These drugs, if found, may be effective in treating cancers with fewer side effects."
Fabric Genomics Partners to Improve Pediatric CareNews
Partnerships with Genomics England, Rady Children's Institute for Genomic Medicine, and The Utah Genome Project demonstrate diagnostic utility of Fabric Genomics' algorithm-based genome analysis.READ MORE
Key Cancer-Linked Proteins Thought to be ‘Undruggable’ Until NowNews
A new study published in Nature, conducted by an alliance between industry and academia involving the University of Liverpool, highlights a new approach to targeting key cancer-linked proteins, thought to be ‘undruggable’.READ MORE
Edico Genome and Fabric Genomics Develop Integrated Solution for Genomics AnalysisNews
Industry leaders partner to provide streamlined variant data analysis solution, with the goal of improving clinical care.READ MORE